http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 25 Jun 2026 10:52:28 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Racura+Oncology+doses+first+patient+in+RC220+lung+cancer+trial/26689947.html <p>Racura Oncology Limited (ASX: RAC) announced that the first patient has been dosed in HARNESS-1, a Phase 1a/b clinical trial evaluating RC220 in combination with osimertinib for patients with epidermal growth factor receptor-mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).</p> <p>The first patient received RC220 at 50 mg/m² by intravenous infusion at Monash Health in Clayton, Victoria, Australia. No adverse events were observed. The treatment was administered by Principal Investigator Associate Professor Surein Arulananda and his team.</p> <p>RC220 is Racura's proprietary formulation of (E,E)-bisantrene, a small molecule designed to target G-quadruplex DNA and RNA structures in oncogenic regulatory regions. The trial is designed http://www.streetinsider.com/FDA/Racura+Oncology+doses+first+patient+in+RC220+lung+cancer+trial/26689947.html Thu, 25 Jun 2026 10:52:28 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/FDA/Racura+Oncology+doses+first+patient+in+RC220+lung+cancer+trial/26689947.html <p>Racura Oncology Limited (ASX: RAC) announced that the first patient has been dosed in HARNESS-1, a Phase 1a/b clinical trial evaluating RC220 in combination with osimertinib for patients with epidermal growth factor receptor-mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).</p> <p>The first patient received RC220 at 50 mg/m² by intravenous infusion at Monash Health in Clayton, Victoria, Australia. No adverse events were observed. The treatment was administered by Principal Investigator Associate Professor Surein Arulananda and his team.</p> <p>RC220 is Racura's proprietary formulation of (E,E)-bisantrene, a small molecule designed to target G-quadruplex DNA and RNA structures in oncogenic regulatory regions. The trial is designed http://www.streetinsider.com/FDA/Racura+Oncology+doses+first+patient+in+RC220+lung+cancer+trial/26689947.html Thu, 25 Jun 2026 10:52:28 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/FDA/Racura+Oncology+doses+first+patient+in+RC220+lung+cancer+trial/26689947.html <p>Racura Oncology Limited (ASX: RAC) announced that the first patient has been dosed in HARNESS-1, a Phase 1a/b clinical trial evaluating RC220 in combination with osimertinib for patients with epidermal growth factor receptor-mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).</p> <p>The first patient received RC220 at 50 mg/m² by intravenous infusion at Monash Health in Clayton, Victoria, Australia. No adverse events were observed. The treatment was administered by Principal Investigator Associate Professor Surein Arulananda and his team.</p> <p>RC220 is Racura's proprietary formulation of (E,E)-bisantrene, a small molecule designed to target G-quadruplex DNA and RNA structures in oncogenic regulatory regions. The trial is designed http://www.streetinsider.com/FDA/Racura+Oncology+doses+first+patient+in+RC220+lung+cancer+trial/26689947.html Thu, 25 Jun 2026 10:52:28 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/FDA/Racura+Oncology+doses+first+patient+in+RC220+lung+cancer+trial/26689947.html <p>Racura Oncology Limited (ASX: RAC) announced that the first patient has been dosed in HARNESS-1, a Phase 1a/b clinical trial evaluating RC220 in combination with osimertinib for patients with epidermal growth factor receptor-mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).</p> <p>The first patient received RC220 at 50 mg/m² by intravenous infusion at Monash Health in Clayton, Victoria, Australia. No adverse events were observed. The treatment was administered by Principal Investigator Associate Professor Surein Arulananda and his team.</p> <p>RC220 is Racura's proprietary formulation of (E,E)-bisantrene, a small molecule designed to target G-quadruplex DNA and RNA structures in oncogenic regulatory regions. The trial is designed http://www.streetinsider.com/FDA/Racura+Oncology+doses+first+patient+in+RC220+lung+cancer+trial/26689947.html Thu, 25 Jun 2026 10:52:28 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/Press+Releases/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html <div class="xn-content"> <p><i><span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance.</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology Limited</span> (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial http://www.streetinsider.com/Press+Releases/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html Thu, 25 Jun 2026 10:51:00 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/Press+Releases/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html <div class="xn-content"> <p><i><span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance.</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology Limited</span> (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial http://www.streetinsider.com/Press+Releases/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html Thu, 25 Jun 2026 10:51:00 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/Press+Releases/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html <div class="xn-content"> <p><i><span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance.</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology Limited</span> (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial http://www.streetinsider.com/Press+Releases/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html Thu, 25 Jun 2026 10:51:00 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/Press+Releases/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html <div class="xn-content"> <p><i><span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance.</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology Limited</span> (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial http://www.streetinsider.com/Press+Releases/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html Thu, 25 Jun 2026 10:51:00 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/PRNewswire/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html <div class="xn-content"> <p><i><span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance.</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology Limited</span> (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial http://www.streetinsider.com/PRNewswire/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html Thu, 25 Jun 2026 10:51:00 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/PRNewswire/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html <div class="xn-content"> <p><i><span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance.</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology Limited</span> (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial http://www.streetinsider.com/PRNewswire/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html Thu, 25 Jun 2026 10:51:00 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/PRNewswire/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html <div class="xn-content"> <p><i><span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance.</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology Limited</span> (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial http://www.streetinsider.com/PRNewswire/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html Thu, 25 Jun 2026 10:51:00 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/PRNewswire/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html <div class="xn-content"> <p><i><span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance.</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology Limited</span> (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial http://www.streetinsider.com/PRNewswire/Racura+Oncology+Doses+First+Patient+in+Phase+1+HARNESS-1+Trial+of+RC220+in+EGFR-Mutant+Non-Small+Cell+Lung+Cancer/26689946.html Thu, 25 Jun 2026 10:51:00 -0400 A.41518098 O.16638313 O.16784813 RAC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+Empyrean+Capital+Partners%2C+LP/26504633.html si-local-file:///var/storage/secattach/20260515/26504633.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+Empyrean+Capital+Partners%2C+LP/26504633.html Fri, 15 May 2026 16:01:00 -0400 O.71487439 RAC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+Empyrean+Capital+Partners%2C+LP/26504633.html si-local-file:///var/storage/secattach/20260515/26504633.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+Empyrean+Capital+Partners%2C+LP/26504633.html Fri, 15 May 2026 16:01:00 -0400 O.71487439 RAC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+First+Trust+Capital+Management+L.P./26504027.html si-local-file:///var/storage/secattach/20260515/26504027.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+First+Trust+Capital+Management+L.P./26504027.html Fri, 15 May 2026 14:58:00 -0400 O.71487439 RAC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+First+Trust+Capital+Management+L.P./26504027.html si-local-file:///var/storage/secattach/20260515/26504027.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+First+Trust+Capital+Management+L.P./26504027.html Fri, 15 May 2026 14:58:00 -0400 O.71487439 RAC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+METEORA+CAPITAL%2C+LLC/26503401.html si-local-file:///var/storage/secattach/20260515/26503401.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+METEORA+CAPITAL%2C+LLC/26503401.html Fri, 15 May 2026 13:40:00 -0400 O.71487439 RAC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+METEORA+CAPITAL%2C+LLC/26503401.html si-local-file:///var/storage/secattach/20260515/26503401.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+METEORA+CAPITAL%2C+LLC/26503401.html Fri, 15 May 2026 13:40:00 -0400 O.71487439 RAC http://www.streetinsider.com/Press+Releases/Racura+Oncology+Announces+Positive+Safety+Review+Committee+Recommendation+in+ongoing+CPACS+Clinical+Trial/26499246.html <div class="xn-content"> <p><i>Safety Review Committee (SRC) gives <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> a recommendation to continue the <span>Cardioprotection and Anticancer Synergy</span> (CPACS) study in advanced solid tumor patients</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span>, an Australian Phase 3 stage clinical biopharmaceutical company, today announced that the independent Safety Review Committee (SRC) has completed its review of safety data from Cohort 1 of the ongoing CPACS clinical trial, evaluating the safety and pharmacokinetics of RC220 alone and in combination with doxorubicin in advanced metastatic solid tumor patients.</p> <p>Following its review, the SRC recommended that http://www.streetinsider.com/Press+Releases/Racura+Oncology+Announces+Positive+Safety+Review+Committee+Recommendation+in+ongoing+CPACS+Clinical+Trial/26499246.html Fri, 15 May 2026 07:06:00 -0400 O.16638313 RAC http://www.streetinsider.com/Press+Releases/Racura+Oncology+Announces+Positive+Safety+Review+Committee+Recommendation+in+ongoing+CPACS+Clinical+Trial/26499246.html <div class="xn-content"> <p><i>Safety Review Committee (SRC) gives <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> a recommendation to continue the <span>Cardioprotection and Anticancer Synergy</span> (CPACS) study in advanced solid tumor patients</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span>, an Australian Phase 3 stage clinical biopharmaceutical company, today announced that the independent Safety Review Committee (SRC) has completed its review of safety data from Cohort 1 of the ongoing CPACS clinical trial, evaluating the safety and pharmacokinetics of RC220 alone and in combination with doxorubicin in advanced metastatic solid tumor patients.</p> <p>Following its review, the SRC recommended that http://www.streetinsider.com/Press+Releases/Racura+Oncology+Announces+Positive+Safety+Review+Committee+Recommendation+in+ongoing+CPACS+Clinical+Trial/26499246.html Fri, 15 May 2026 07:06:00 -0400 O.16638313 RAC http://www.streetinsider.com/PRNewswire/Racura+Oncology+Announces+Positive+Safety+Review+Committee+Recommendation+in+ongoing+CPACS+Clinical+Trial/26499246.html <div class="xn-content"> <p><i>Safety Review Committee (SRC) gives <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> a recommendation to continue the <span>Cardioprotection and Anticancer Synergy</span> (CPACS) study in advanced solid tumor patients</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span>, an Australian Phase 3 stage clinical biopharmaceutical company, today announced that the independent Safety Review Committee (SRC) has completed its review of safety data from Cohort 1 of the ongoing CPACS clinical trial, evaluating the safety and pharmacokinetics of RC220 alone and in combination with doxorubicin in advanced metastatic solid tumor patients.</p> <p>Following its review, the SRC recommended that http://www.streetinsider.com/PRNewswire/Racura+Oncology+Announces+Positive+Safety+Review+Committee+Recommendation+in+ongoing+CPACS+Clinical+Trial/26499246.html Fri, 15 May 2026 07:06:00 -0400 O.16638313 RAC http://www.streetinsider.com/PRNewswire/Racura+Oncology+Announces+Positive+Safety+Review+Committee+Recommendation+in+ongoing+CPACS+Clinical+Trial/26499246.html <div class="xn-content"> <p><i>Safety Review Committee (SRC) gives <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span> a recommendation to continue the <span>Cardioprotection and Anticancer Synergy</span> (CPACS) study in advanced solid tumor patients</i></p><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>May 15, 2026</chron></span> /PRNewswire/ -- <span value="Australia:RAC" idsrc="xmltag.org" >Racura Oncology</span>, an Australian Phase 3 stage clinical biopharmaceutical company, today announced that the independent Safety Review Committee (SRC) has completed its review of safety data from Cohort 1 of the ongoing CPACS clinical trial, evaluating the safety and pharmacokinetics of RC220 alone and in combination with doxorubicin in advanced metastatic solid tumor patients.</p> <p>Following its review, the SRC recommended that http://www.streetinsider.com/PRNewswire/Racura+Oncology+Announces+Positive+Safety+Review+Committee+Recommendation+in+ongoing+CPACS+Clinical+Trial/26499246.html Fri, 15 May 2026 07:06:00 -0400 O.16638313 RAC http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Rithm+Acquisition+Corp.+++For%3A+Mar+31/26478586.html si-local-file:///var/storage/secattach/20260512/26478586.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Rithm+Acquisition+Corp.+++For%3A+Mar+31/26478586.html Tue, 12 May 2026 16:31:00 -0400 O.71487439 RAC http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Rithm+Acquisition+Corp.+++For%3A+Mar+31/26478586.html si-local-file:///var/storage/secattach/20260512/26478586.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Rithm+Acquisition+Corp.+++For%3A+Mar+31/26478586.html Tue, 12 May 2026 16:31:00 -0400 O.71487439 RAC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+Hudson+Bay+Capital+Management+LP/26468260.html si-local-file:///var/storage/secattach/20260511/26468260.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rithm+Acquisition+Corp.++++++++++++++++Filed+by%3A+Hudson+Bay+Capital+Management+LP/26468260.html Mon, 11 May 2026 14:46:00 -0400 O.71487439 RAC